UnknownPHASE2, PHASE3NCT05057130

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Blokhin's Russian Cancer Research Center
Principal Investigator
Beniamin Bokhyan, PhD, MD, PhD
N.N. Blokhin NMRCO
Intervention
Doxorubicin, Cisplatin, Methotrexate(drug)
Enrollment
50 enrolled
Eligibility
24-40 years · All sexes
Timeline
2022 – 2024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05057130 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials